Dilsher S. Dhoot, MD

A look at current therapies, clinical trial results, patient education, and emerging options for managing this progressive retinal disease.

At ARVO 2025, in Salt Lake City, Utah, Dilsher Dhoot, MD, FASRS, and Mark Barakat, MD, talked about the PHOTON trial, 8 mg versus 2 mg during the matched dosing phase, and outcomes of shortened, maintained, or extended dosing intervals

Dilsher S. Dhoot, MD discusses a recent case-based roundtable meeting on anti-VEGF biosimilars, highlighting the first of two case discussions.

Dilsher S. Dhoot, MD discusses a recent case-based roundtable meeting on anti-VEGF biosimilars, highlighting the first of two case discussions.

Dilsher Dhoot, MD, presents two cases involving DME and CRVO, that show remarkable anatomical improvement with a biosimilar comparable to those achieved with reference biologics.

Dilsher Dhoot, MD, provides an overview of biosimilars in retinal diseases and discusses how he identifies patients suitable for biosimilar therapy.

Dilsher S. Dhoot, MD, and A. Paul Chous, MA, OD, FAAO, discuss future directions and unmet needs in the field of retinal eye disease.

Key opinion leaders discuss the barriers to co-management of retinal eye disease.

Dilsher S. Dhoot, MD, and A. Paul Chous, MA, OD, FAAO, discuss the transition of care from ophthalmologist to optometrist once a patient has completed active treatment for retinal eye disease.

Experts in the field of retinal eye disorders discuss the role of injectable anti-VEGF inhibitors and how they have changed the treatment landscape.

Dilsher S. Dhoot, MD, leads a discussion about the treatment landscape of retinal eye disorders.

Key opinion leaders discuss how co-management affects the patient-provider relationship in the treatment of retinal eye disorders.

A. Paul Chous, MA, OD, FAAO, leads a discussion about the optimal circumstances for optometrists and ophthalmologists to work together to manage a patient with retinal eye disorders.

Experts in the field of retinal eye disorders discuss how the COVID-19 pandemic and use of telemedicine has affected communication between optometrists, ophthalmologists, patients, and providers.

Experts in the field of retinal eye disorders talk about the role of ophthalmologists and optometrists in regard to patient education and communication.

Dilsher S. Dhoot, MD, and A. Paul Chous, MA, OD, FAAO, discuss the American Academy of Ophthalmology (AAO) guidelines on co-management between optometrists and ophthalmologists in retinal eye disorders.

Experts discuss the challenges regarding the treatment of retinal disorders, and how co-management can potentially address those challenges.

Dilsher S. Dhoot, MD, and A. Paul Chous, MA, OD, FAAO, discuss the co-management of retinal eye disorders and provide a clinical overview of the disease.